CN1244391A - Long-acting analgesic used mainly for operational cut and traumatic wound - Google Patents
Long-acting analgesic used mainly for operational cut and traumatic wound Download PDFInfo
- Publication number
- CN1244391A CN1244391A CN 99116401 CN99116401A CN1244391A CN 1244391 A CN1244391 A CN 1244391A CN 99116401 CN99116401 CN 99116401 CN 99116401 A CN99116401 A CN 99116401A CN 1244391 A CN1244391 A CN 1244391A
- Authority
- CN
- China
- Prior art keywords
- long
- analgesic
- pain
- blue
- acting analgesic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The long-acting analgesic consists of gluanylate of methylene blues as cyclase inhibitor, lidocaines as local anesthetics and medicine carrier. Methylene blues can repair nerve ending after producing some damage and the repair period is 20-30 days, so that the present invention uses it as long-acting analgesic. The local anesthetics eliminates the pain during damage stage. The analgesic comes in various forms, including injectio, gel, cream, and has pain killing effect as long as 20-30 days on operational cut, traumatic wound, burn and scald, toothache, sharp pain of later-stage cancer, etc.
Description
The present invention relates to a kind of pain of removing, particularly can remove the analgesic of pain such as operation back wound, trauma wounds over a long time.
Surgical operation has otch and wound and exists early for treating a kind of necessary way of the disease that has after the operation, it can cause intensive pain, and this pain has the serious effect of paying, and will directly influence postoperative recovery.The somebody abandons operation because of fearing pain, take conservative treatment, so that the situation of delay treatment happens occasionally.The severe pain that also has cancer of late stage in addition, the causalgia of burn and scald, the twinge of traumatic injury of skin etc., not only cruel torment patient also often makes families of patients heart-broken.
For removing above-mentioned misery, medical personnel and medical worker be constantly effort once, has invented some analgesic, the pain relieving injection, and what they had has the effect of paying to nervous system, and what have also can make patient habit-forming as dolantin etc., and harmful patient's is healthy.The most important is that they have only the analgesic effect of short time, get to use endlessly.
The objective of the invention is at the existing problem of above-mentioned analgesic, aim to provide and a kind ofly can solve local pain over a long time, particularly because of the analgesic of safe and effective, the no any pair of effect of the caused pain such as back wound, trauma wounds of performing the operation.
The implementation of the object of the invention is, a kind of long-acting analgesic that is mainly used in operation back wound and trauma wounds, and it is composed as follows:
A, black glycosides salt cyclisation inhibitor are as serge blue 0.03-0.5g
B, local anesthetic are as lignocaine 0.2-3.0g
C, medicine carrier add to 100g or 100ml.
The present invention has selected black glycosides salt cyclase inhibitors for use, except that inferior orchid, also include colourless serge blue, 6-anilino-quinoline-58-quinone, N-methyl hydroxylamine hydrochlorate, hydroxylamine, acidum ethacrynicum, retinol, toluidine blue (VA1), dimethyl diaminophenazine chloride, tetrazolium father-in-law salt purple, tetrachloro dabequine quinone etc.They have stronger affinity to local nervous system, and the nerve ending medullary substance is had detrimental effect earlier, make function of nervous system temporarily be affected, and reach the purpose of removing pain.After treating 20-30 days, the nerve ending medullary substance of infringement can be recovered again, and wound or wound recovered substantially or fully recovered this moment, did not need pain relieving again.Serge blues etc. approximately have 4 hours severe pain sense when nerve ending is damaged, the present invention has selected lignocaine, procaine, bupivacaine and its esters etc. with local anesthesia effect for use, eliminates the pain in this stage.
The present invention adopts universal medication with carrier and conventional pharmaceutical methods, and again according to state of an illness difference, the agents area difference can be made into injection, gel, cream, patch, aerosol etc.The reversibility that dosage in the various dosage forms must enough produce the nerve ending medullary substance suppresses, the effect of promptly damage earlier, the back being repaired.
This medicament is to various operations, as surgical operation, hemorrhoids operation, tooth pulling surgery, foreskin operation, caesarean operation wound and wound; Skin injury, as caused pain such as scratch, laceration, knife injury, burn and scald, and toothache, anus twinge, terminal cancer severe pain etc. all have 20-30 days analgesic effect.
This medicament only need be used once when using, and also dose can be divided and use several times, and applied once is identical with the final effect that gradation is used.
The application method of this medicament has: Intradermal, subcutaneous or intramuscular injection, and to the spraying of need pain relieving position, ointment, cream apply or paste, and stype, adhesive bandage, gauze, semipermeable membrane, conduit are directed at required pain relieving position etc.
Enumerate formulation Example of the present invention below:
The injection prescription:
Example 1: serge blue 0.03 gram
Lidocaine hydrochloride 0.2 gram
Water for injection adds to 100 milliliters
Example 2: serge blue 0.2 gram
Lidocaine hydrochloride 1.0 grams
Water for injection adds to 100 milliliters
Example 3: gel prescription
Serge blue 0.05 gram
Lidocaine hydrochloride 0.5 gram
Kappa Pu (940) 0.5 grams
Ethanol 10.0 grams
Propylene glycol 10.0 grams
Sodium hydroxide is an amount of
Water adds to 100 milliliters
Example 4: cream prescription
Serge blue 0.1 gram
Lidocaine hydrochloride 1.0 grams
Cream base adds to 100 grams
Example 5: long-acting analgesic adhesive bandage prescription
Serge blue 0.1 gram
Lidocaine hydrochloride 2.5 grams
Adhesive bandage back lining materials aerosol prescription: example 6: serge blue 0.05 gram
Lidocaine hydrochloride 0.5 gram
An amount of example 7 of propellant: serge blue 0.4 gram
Lidocaine hydrochloride 1.0 grams
The Chinese and English title and the molecular formula of an amount of serge blue of propellant, lignocaine etc. are seen attached sheet.
Mcthylene Blue (serge blue)
Leuko Methylenc Blue (colourless serge blue)
6-anilinoquinoline-5,8-quinc..c (6-anilino-quinoline-58 quinone)
N-methyl hydroxylamlne hydrochlorlde
(N-methyl hydroxylamine hydrochlorate)
H
2NOH·HClhydroxylamine?hydrochloride
(oxammonium hydrochloride .)
Ethacrynic acid (acidum ethacrynicum)
Rounol (retinol (VA1))
Totuidine Blue (toluidine blue)
Neutral Rcd (dimethyl diaminophenazine chloride)
Tetrazolium Violet (tetrazolium () purple)
Chloranil (tetrachloroquinone)
Claims (4)
1, a kind of long-acting analgesic that is mainly used in operation back wound and trauma wounds is characterized in that composed as follows:
A, black glycosides salt cyclisation inhibitor are as serge blue 0.03-0.5g
B, local anesthetic are as lignocaine 0.2-3.0g
C, medicine carrier add to 100g or 100ml.
2, analgesic according to claim 1 is characterized in that black glycosides salt cyclase inhibitors also includes: colourless serge blue, 6-glafenine-58-quinone, N-methyl hydroxylamine hydrochlorate, oxammonium hydrochloride., acidum ethacrynicum, retinol, toluidine blue (VA1), dimethyl diaminophenazine chloride, tetrazolium father-in-law purple, four oxygen benzoquinone.
3, analgesic according to claim 1 is characterized in that local anesthetic also includes: procaine, bupivacaine and lignocaine salt.
4, analgesic according to claim 1 is characterized in that with the carrier difference injection, gel, cream, patch, aerosol being arranged according to medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99116401A CN1108156C (en) | 1999-03-26 | 1999-03-26 | Long-acting analgesic used mainly for operational cut and traumatic wound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99116401A CN1108156C (en) | 1999-03-26 | 1999-03-26 | Long-acting analgesic used mainly for operational cut and traumatic wound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1244391A true CN1244391A (en) | 2000-02-16 |
| CN1108156C CN1108156C (en) | 2003-05-14 |
Family
ID=5279222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99116401A Expired - Fee Related CN1108156C (en) | 1999-03-26 | 1999-03-26 | Long-acting analgesic used mainly for operational cut and traumatic wound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1108156C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407953B2 (en) | 2004-09-20 | 2008-08-05 | Photopharmica Limited | Wound healing |
| CN109276718A (en) * | 2018-10-09 | 2019-01-29 | 蓝可彰 | Combined closing liquid and its application containing methylthioninium chloride injection |
-
1999
- 1999-03-26 CN CN99116401A patent/CN1108156C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407953B2 (en) | 2004-09-20 | 2008-08-05 | Photopharmica Limited | Wound healing |
| CN109276718A (en) * | 2018-10-09 | 2019-01-29 | 蓝可彰 | Combined closing liquid and its application containing methylthioninium chloride injection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1108156C (en) | 2003-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Thomas et al. | Dexamethasone reduces the severity of postoperative sore throat | |
| Park et al. | Application of triamcinolone acetonide paste to the endotracheal tube reduces postoperative sore throat: a randomized controlled trial | |
| WO2014126370A1 (en) | Film-forming pharmaceutical composition for wound healing and method for preparing the same | |
| KR19990044182A (en) | Peripheral active opioids | |
| AU2004290463A1 (en) | Method and composition for treatment of cutaneous lesions | |
| US20110044917A1 (en) | Dental composition for treating peri-implantitis | |
| KR101921363B1 (en) | Proteolytic extract from bromelain for the treatment of connective tissue disorders | |
| CN1244391A (en) | Long-acting analgesic used mainly for operational cut and traumatic wound | |
| WO2014129818A1 (en) | Pharmaceutical composition for preventing or treating diabetic wound | |
| WO2000030630A1 (en) | Combination products of a guanylate cyclase inhibitor and a local anesthetic for pain relief | |
| EP3085371A1 (en) | Parthenolide and its derivatives for use in the treatment of axonal damage | |
| WO2006085127A1 (en) | Topical compositions | |
| Hanifin | Ethylene oxide dermatitis | |
| CN1259052C (en) | Medicinal composition for treating burn and scald and preparing method | |
| KR101008052B1 (en) | Percutaneous absorption type cerebral protective agent | |
| AU703691B2 (en) | Irritation relief using nonsteroidal anti-inflammatory compounds | |
| LASSUS et al. | A Comparative Study of Topical Analgesia with a Lidocaine/Prilocaine Cream (EMLA A) and Infiltration Anesthesia for Laser Surgery of Genital Warts in Men | |
| RU2367424C1 (en) | Technique for anesthesia following minimally invasive abdominal surgeries | |
| CN116135222B (en) | Hemostatic composition containing cannabidiol and application of hemostatic composition as liquid bandage | |
| BR112015002030B1 (en) | Use of a composition comprising pentameric type a procyanidin, trimeric procyanidin and tetrameric procyanidin, optionally together with a pharmaceutically acceptable excipient | |
| Sonani et al. | KATUPILACHURNA IN THE MANAGEMENT OF DUSTAVRANA WSR TO VENOUS ULCER: A SINGLE CASE REPORT | |
| US20080139584A1 (en) | Method for healing a wound | |
| RU2208402C1 (en) | Method for thrombosis prophylaxis in vessels of transferred fragment | |
| Hiller et al. | Intravenous indomethacin prevents venipuncture inflammatory sequelae | |
| RU2323721C2 (en) | Local anesthetic and antiseptic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20030514 Termination date: 20130326 |